FOSTER CITY (CBS/AP) — Drugmaker Gilead Sciences Inc. has halted several patient studies of its cancer drug, Zydelig, because of increased risk of death and serious side effects.
The company told The Associated Press the “adverse events” were spotted during an ongoing review of late-stage testing in patients with chronic lymphocytic leukemia, a blood cancer, and patients with relapsed non-Hodgkin’s lymphoma, a cancer of the infection-fighting lymphatic system.READ MORE: 49ers Playoffs: Die-Hard Fans Offer Sendoff, Head To Frigid Green Bay For Showdown Vs. Packers
Nathan Kaiser, a spokesman for the Foster City company, wouldn’t disclose details, including how many patients died or suffered serious side effects.READ MORE: Astronomers Atop Mount Hamilton Join Battle Against Digital Billboards Going Up In San Jose
“We are conducting a comprehensive review of all ongoing studies and are consulting with regulatory authorities,” Kaiser wrote in an email Tuesday.
Zydelig is approved for treating follicular B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia in patients who have failed other treatments.MORE NEWS: Injury Collision Closes All Northbound Lanes of Hwy 101 in San Francisco
TM and © Copyright 2016 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2016 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.